Biodexa Pharmaceuticals Plc — Form F-1
Filed July 15, 2026 · analyzed by the Registration Agent
F-1
▼ Likely negative
significance 12/100
What the filing says
Biodexa Pharmaceuticals PLC filed a Form F-1 registration statement on July 15, 2026 to permit resale by selling shareholders of up to 1,277.5 billion ordinary shares (2.56 billion ADSs at 500,000 shares per ADS) representing potential proceeds from warrant exercises. The securities consist of: 175.4B shares from pre-funded warrants (~$0.9M gross proceeds collected), 141.5B from Series M warrants (~$0.8M), 350.9B from Series N warrants (~$1.0M), and 609.8B from Series O warrants (~$1.7M), all closed July 1, 2026. Additionally, Biodexa drew $8.9M under a $35M equity line of credit with C/M Capital Master Fund through July 1, 2026, issuing 57.6B ordinary shares.
Why this rating
Massive dilution via warrant exercises and ELOC draws; routine warrant issuance filing; company size unclear but extreme share count expansion suggests distressed capital structure.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.